FibroBiologics, Inc.
FBLG- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001958777
No open-market purchases or sales by FibroBiologics, Inc. insiders were filed in the last 90 days; 16 institutions reported holding it in 13F filings for Q2 2026, worth $269.6K in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in FibroBiologics, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 16
- −1 vs. Q1 2026
- Shares held
- 284.9K
- +64.3K (+29.1%) vs. Q1 2026
- Total value
- $269.6K
- −$21.4K (−7.4%) vs. Q1 2026
- New holders
- 3
- 5 more added
- Sold out
- 4
- 4 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting FBLG on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 16 | $269.6K |
| Q1 2026 | 17 | $291.1K |
| Q4 2025 | 46 | $993.8K |
| Q3 2025 | 55 | $3.28M |
| Q2 2025 | 59 | $3.75M |
| Q1 2025 | 65 | $5.81M |
| Q4 2024 | 64 | $11.9M |
| Q3 2024 | 61 | $16.8M |
| Q2 2024 | 50 | $17.4M |
| Q1 2024 | 17 | $5.43M |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding FibroBiologics, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Cascade Financial Partners, LLC | 108,828 | $103.1K | 0.01% | +92,400+562.5% | Added |
| Fund Evaluation Group, LLC | 51,794 | $49.1K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 30,299 | $28.7K | 0.00% | +690+2.3% | Added |
| Vanguard Capital Management LLC | 27,769 | $26.3K | 0.00% | −39,896−59.0% | Reduced |
| Qube Research & Technologies Ltd | 24,313 | $23.0K | 0.00% | +24,313 | New |
| BlackRock, Inc. | 18,238 | $17.3K | 0.00% | −6,409−26.0% | Reduced |
| Barclays PLC | 7,243 | $6.86K | 0.00% | +7,243 | New |
| Vanguard Fiduciary Trust Co | 6,380 | $6.05K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 4,728 | $4.48K | 0.00% | +4,268+927.8% | Added |
| Advisor Group Holdings, Inc. | 2,404 | $2.28K | 0.00% | +2,250+1,461.0% | Added |
| UBS Group AG | 1,073 | $1.02K | 0.00% | −4,648−81.2% | Reduced |
| Royal Bank of Canada | 1,522 | $1.00K | 0.00% | +1,336+718.3% | Added |
| Islay Capital Management, LLC | 169 | $160 | 0.00% | 00.0% | Unchanged |
| Grove Bank & Trust | 100 | $95 | 0.00% | +100 | New |
| BNP Paribas Arbitrage, SA | 64 | $61 | 0.00% | −2−3.0% | Reduced |
| Allworth Financial LP | 13 | $13 | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −15,997−100.0% | Sold out |
| GWM Advisors LLC | 0 | $0 | 0.00% | −845−100.0% | Sold out |
| Vanguard Global Advisers, LLC | 0 | $0 | 0.00% | −536−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −10−100.0% | Sold out |